PTIX Stock Summary and Trading Ideas (Protagenic Therapeutics | NASDAQ:PTIX)

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Protagenic Therapeutics trades on the NASDAQ stock market under the symbol PTIX.

As of March 5, 2025, PTIX stock price declined to $0.33 with 1,935,930 million shares trading.

PTIX has a beta of -0.19, meaning it tends to be less sensitive to market movements. PTIX has a correlation of 0.00 to the broad based SPY ETF.

PTIX has a market cap of $2.42 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PTIX traded as high as $4.20 and as low as $.24.

The top ETF exchange traded funds that PTIX belongs to (by Net Assets): VXF.

PTIX has underperformed the market in the last year with a return of -66.6%, while the SPY ETF gained +15.2%. In the last 3 month period, PTIX fell short of the market, returning -38.9%, while SPY returned -3.7%. However, in the most recent 2 weeks PTIX has outperformed the stock market by returning +25.1%, while SPY returned -4.6%.

PTIX support price is $.33 and resistance is $.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTIX shares will trade within this expected range on the day.